Polyplus-transfection SA, of Strasbourg, France, said it has granted Roche Glycart AG, a Swiss biotechnology company fully owned by Roche, a nonexclusive license to use polyethylenimine (PEI) for in vitro transfection applications for research purposes. The license will enable Roche Glycart AG to use PEI in its research to produce antibody-based products.